Vous avez cherché: pathogenesis (Anglais - Maltais)

the pathogenesis of sle is not well understood.
il-patoġenesi ta’ sle għadha mhix mifhuma sew.

as the precise pathogenesis is unknown, only supportive measures can be recommended.
billi l-patoġenesi preċiża mhijiex magħrufa, miżuri ta' appoġġ biss jistgħu jiġu rakkomandati.

• role of the cellular immune system in the pathogenesis of type 1 diabetes.
l-imsieħba ta’toneca jirrappreżentaw ħdax-il pajjiż ta’ l-ue u jemmnu li l-proġett jista’jagħmel differenza, forsi xi darba jkunu jistgħu jiġu skoperti l-kawżi bażi tad-diabetes mellitus tat-tip 1 u li jiġu identifikati għanijiet ġodda għall-prevenzjoni, dijanjożi u trattament.

il-6 has been implicated in the pathogenesis of diseases including inflammatory diseases, osteoporosis and neoplasia.
il-6 ġie implikat fil-patoġenesi tal-mard fosthom mard infjammatorju, osteoporożi u neoplażja.

elevated concentrations of il-17a have been implicated in the pathogenesis of psoriasis by promoting keratinocyte proliferation and activation.
konċentrazzjonijiet għolja ta’ il-17a ġew implikati fil-patoġenesi tal-psorjasi billi jippromwovu l-proliferazzjoni u l-attivazzjoni tal-keratinoċiti.

the complicated nature of these cases makes it impossible to determine what role, if any, rasagiline played in their pathogenesis.
in- natura kumplikata ta ’ dawn il- każi tagħmilha impossibli li issir taf jekk kellux parti jew x’ parti kellu rasagiline fil- patoġenesi tagħhom.

aberrant hh signalling has been linked to the pathogenesis of several types of cancer, including basal cell carcinoma (bcc).
sinjali anormali hh kienu marbuta mal-patoġenesi ta’ bosta tipi ta’ kanċer inkluż tal-karċinoma taċ- ċellola bażilari (bcc).

based on the rodent-specific pathogenesis and mechanism for these findings, they are not considered to represent an increased carcinogenic risk for patients taking pazopanib.
abbażi tal-patoġenesi u tal-mekkaniżmi speċifiċi għall-annimali gerriema li rriżultaw minn dawn is-sejbiet, dawn ma jitqisux rappreżentattivi ta’ żieda fir-riskju karċinoġeniku għall-pazjenti li jieħdu pazopanib.

the result is a reduction in intraocular pressure (iop) which is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss.
dan iwassal għal tnaqqis tal-pressjoni fil-għajn (iop) li huwa il-fattur ta’ riskju għoli fil-patoġenesi ta’ ħsara fl-optic nerv u fit-telf tal-vista tal-glawkoma.

the mechanism of action is the inhibition of pde4, a major cyclic adenosine monophosphate (camp)-metabolizing enzyme found in structural and inflammatory cells important to the pathogenesis of copd.
il-mekkaniżmu tal-azzjoni hi l-inibizzjoni ta’ pde4, enzima maġġuri ċiklika li timmetabolizza adenosine monophosphate (camp) li tinsab f’ċelluli strutturali u infjammatorji li huma importanti għall-patoġenesi ta’ copd.

although the pathogenesis of als is not completely elucidated, it is suggested that glutamate (the primary excitatory neurotransmitter in the central nervous system) plays a role for cell death in the disease.
għalkemm il-mod kif tiżviluppa l-marda als mhux magħruf kompletament, hemm il-possibbiltà li glutamate (stimulant prinċipali newrotransmittur fis-sistema ċentrali nervuża) għandu rwol fil-mewt taċ-ċelluli f’din il-marda.

constitutive activation of the pdgf receptor or the abl protein tyrosine kinases as a consequence of fusion to diverse partner proteins or constitutive production of pdgf have been implicated in the pathogenesis of mds/mpd, hes/cel and dfsp.
attivazzjoni kostituttiva tar-riċettur pdgf jew abl protein tyrosine kinases bħala konsegwenza tal-fużjoni ma’ proteini diversi imseħħbin jew produzzjoni kostituttiva ta’ pdgf kienu implikati fil-patoġenesi ta’ mds/mpd, hes/cel u dfsp.

although in the majority of cases the information was too limited to allow a causality assessment, confounding factors such as pre-existing lupus, including potential incipient sle, were present in many of the remaining cases and the pathogenesis of sle/drug-induced lupus is still poorly understood and probably multifactorial, it does not appear unreasonable that xolair, a drug that forms immune complexes with ige with the potential to induce immune complex injury and for which events such as serum sickness have been rarely reported, could play a role in the pathogenesis of sle/drug-induced lupus.
minkejja li fil-biċċa l-kbira tal-każijiet it-tagħrif kien wisq limitat sabiex tkun tista’ sseħħ evalwazzjoni tal- każwalità, fatturi li ħolqu konfużjoni fosthom lupus eżistenti minn qabel, inkluż bidu potenzjali ta’ sle kienu preżenti f’bosta mill-każijiet li kien għad fadal u patoġenesi ta’ sle/lupus minħabba mediċini mhux magħrufa u x’aktarx multifattorjali, ma jidhirx irraġonevoli li xolair, mediċina li tifforma kumplessi immuni b’ige bil-potenzjal li tinduċi ħsara fil-kumpless immuni u li minħabba f’hekk episodji rari fosthom ta’ mard minħabba s-serum ġew irrappurtati, xorta jaf ikollu sehem fil- patoġenesi ta’ sle/lupus minħabba mediċini.